LPG
MCID: LPP002
MIFTS: 46

Lipoprotein Glomerulopathy (LPG) malady

Categories: Genetic diseases, Nephrological diseases, Metabolic diseases, Endocrine diseases, Rare diseases

Aliases & Classifications for Lipoprotein Glomerulopathy

About this section
Sources:
12diseasecard, 24GeneTests, 27GTR, 31ICD10 via Orphanet, 37MedGen, 52OMIM, 54Orphanet, 68UMLS, 70UniProtKB/Swiss-Prot
See all MalaCards sources

Aliases & Descriptions for Lipoprotein Glomerulopathy:

Name: Lipoprotein Glomerulopathy 52 24 54 70 27 12 68
 
Lpg 24 54 70

Characteristics:

Orphanet epidemiological data:

54
lipoprotein glomerulopathy:
Inheritance: Autosomal dominant; Age of onset: All ages

Classifications:



External Ids:

OMIM52 611771
Orphanet54 ORPHA329481
ICD10 via Orphanet31 N07.8
MedGen37 C2673196

Summaries for Lipoprotein Glomerulopathy

About this section
OMIM:52 Lipoprotein glomerulopathy is an uncommon kidney disease characterized by proteinuria, progressive kidney failure, and... (611771) more...

MalaCards based summary: Lipoprotein Glomerulopathy, also known as LPG, is related to zap-70 deficiency and cetp-related hyperalphalipoproteinemia, and has symptoms including renal insufficiency, proteinuria and mesangial abnormality. An important gene associated with Lipoprotein Glomerulopathy is APOE (Apolipoprotein E), and among its related pathways are amb2 Integrin signaling and A-beta Pathways: Uptake and Degradation. Affiliated tissues include kidney and endothelial, and related mouse phenotypes are Increased LDL uptake and Decreased free cholesterol.

UniProtKB/Swiss-Prot:70 Lipoprotein glomerulopathy: Uncommon kidney disease characterized by proteinuria, progressive kidney failure, and distinctive lipoprotein thrombi in glomerular capillaries.

Related Diseases for Lipoprotein Glomerulopathy

About this section

Diseases related to Lipoprotein Glomerulopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 57)
idRelated DiseaseScoreTop Affiliating Genes
1zap-70 deficiency10.2APOB, APOE
2cetp-related hyperalphalipoproteinemia10.2APOB, APOE
3joint disorders10.2APOB, APOE
4spinocerebellar ataxia 2010.1APOB, LPA
5nephrotic syndrome10.1
6malignant hyperthermia susceptibility 110.1APOB, LPA
7primary pigmented nodular adrenocortical disease10.1APOB, APOE
8anaplastic ganglioglioma10.1LCAT, LPA
9gait apraxia10.1APOB, APOE
10glaucoma 1, open angle, n10.1APOE, CLU
11fetal warfarin syndrome10.1APOB, LCAT
12tyrosinemia, type ii10.0APOA2, LCAT
13optic nerve neoplasm10.0APOB, APOE, LPA
14syringocystadenoma papilliferum10.0APOE, CLU
15myelophthisic anemia10.0APOB, APOE, LPA
16budd-chiari syndrome10.0APOB, APOE, LPA
17mannosidosis, beta10.0APOB, APOE, LCAT
18dyserythropoietic anemia, congenital, type ii10.0APOE, LCAT, LPA
19bleeding disorder, east texas type10.0APOA2, APOB, APOE
20pontocerebellar hypoplasia, type 1010.0APOE, LDLR
21atherosclerosis9.9
22familial progressive cardiac conduction defect9.9APOA2, APOE, LCAT
23intra-abdominal lymph node mast cell malignancy9.9APOE, LPA
24van maldergem syndrome 29.9APOA2, LPA
25keratoconus 49.9APOB, APOE, LDLR
26severe intellectual disability-progressive postnatal microcephaly- midline stereotypic hand movements syndrome9.9APOB, APOE, LDLR
27asphyxia neonatorum9.9APOE, LDLR, LPA
28cervix small cell carcinoma9.9APOB, APOE, LDLR
29fibrosarcoma of bone9.9APOB, LDLR, LPA
30chondrocalcinosis with early-onset osteoarthritis9.8APOB, APOE, LCAT, LPA
31albinism, oculocutaneous, type v9.8APOA2, APOB, APOE, LPA
32von hippel-lindau syndrome9.8APOB, APOE, LCAT, LPA
33skin squamous cell carcinoma9.7APOB, APOE, LDLR, LPA
34autoimmune-related retinopathy and optic neuropathy9.7APOB, APOE, LDLR, LPA
35pericarditis9.7APOB, APOE, LDLR, LPA
36glomerulonephritis9.7
37malignant hypertension9.7
38psoriasis9.7
39fibrillary glomerulonephritis9.7
40endotheliitis9.7
41dentinogenesis imperfecta type 29.7APOB, APOE, LCAT, LDLR
42hypercholesterolemia, due to ligand-defective apo b9.7APOB, APOE, LCAT, LDLR
43bird fancier's lung9.6APOA2, APOB, APOE, LCAT, LPA
44neuropathy, hereditary sensory and autonomic, type ia9.6APOA2, APOB, APOE, LCAT, LPA
45maturity-onset diabetes of the young 69.6APOA2, APOB, APOE, LCAT, LPA
46acute apical periodontitis9.5APOB, APOE, LCAT, LDLR, LPA
47lipomatosis9.5APOB, APOE, LCAT, LDLR, LPA
48immunodeficiency 189.5APOA2, APOB, APOE, LDLR, LPA
49pyrimidine metabolic disorder9.5APOA2, APOB, APOE, LDLR, LPA
50myocardial infarction9.5APOA2, APOB, APOE, LDLR, LPA

Graphical network of the top 20 diseases related to Lipoprotein Glomerulopathy:



Diseases related to lipoprotein glomerulopathy

Symptoms & Phenotypes for Lipoprotein Glomerulopathy

About this section


Clinical features from OMIM:

611771

Human phenotypes related to Lipoprotein Glomerulopathy:

 64
id Description HPO Frequency HPO Source Accession
1 renal insufficiency64 HP:0000083
2 proteinuria64 HP:0000093
3 mesangial abnormality64 HP:0001966
4 glomerulopathy64 HP:0100820

GenomeRNAi Phenotypes related to Lipoprotein Glomerulopathy according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00340-A-110.0APOE, LDLR
2GR00340-A-29.1APOB, APOE, LDLR, LPA

MGI Mouse Phenotypes related to Lipoprotein Glomerulopathy according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053858.5APOB, APOE, CLU, LCAT, LDLR
2MP:00053708.3APOB, APOE, LCAT, LDLR

Drugs & Therapeutics for Lipoprotein Glomerulopathy

About this section

Drugs for Lipoprotein Glomerulopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 9)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Irbesartanapproved, investigational102138402-11-63749
Synonyms:
138402-11-6
2-Butyl-3-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-1,3-diazaspiro(4.4)non-1-en-4-one
2-Butyl-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]1,3-diaza-spiro[4.4]non-1-en-4-one
2-Butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
2-butyl-3-[ p -( o -1 H -tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4,4]non-1-en-4-one
2-butyl-3-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-1,3-diaza-spiro[
2-butyl-3-[2'-(1h-tetrazol-5-yl)biphenyl-4-ylmethyl]1,3-diaza-spiro[
2-butyl-3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4.4]non-1-en-4-one
2-butyl-3-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
2-butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
2-n-butyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1,3-diazaspiro(4,4)non-1-en-4-one
8-butyl-7-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-7,9-diazaspiro[4.4]non-8-en-6-one
AC-537
AC1L1GMK
Aprovel
Avalide
Avapro
Avapro (TN)
BIDD:GT0347
BMS 186295
BMS Brand of Irbesartan
BMS-186295
BMS-186295, SR-47436, Aprovel, Karvea, Irbesartan
BRD-K60038276-001-02-5
BSPBio_002687
Bio-0053
Bristol Myers Brand of Irbesartan
C07469
C081309
C25H28N6O
CHEBI:5959
CHEMBL1513
CID3749
CPD000466306
D00523
DB01029
HMS1922J05
HMS2051L08
HMS2093E16
 
I06-0690
Irbesarran
Irbesartan
Irbesartan (JAN/USAN/INN)
Irbesartan [USAN:INN]
Irbesartan [Usan:Inn]
Irbetan
Jsp002315
KBio2_002231
KBio2_004799
KBio2_007367
KBio3_001907
KBioGR_001603
KBioSS_002231
Karvea
L000319
LS-60064
Lrbesartan
MLS000759408
MLS001424099
MolPort-003-666-550
NCGC00095122-01
NCGC00095122-02
NCGC00095122-03
S1507_Selleck
SAM001246548
SMR000466306
SPBio_001889
SPECTRUM1504259
SR 47436
SR-47436
STK645362
Sanofi Winthrop Brand of Irbesartan
Spectrum2_001675
Spectrum3_000994
Spectrum4_001122
Spectrum5_001288
Spectrum_001751
TL8000875
UNII-J0E2756Z7N
irbesartan
2
Sevelamerapproved7452757-95-6, 152751-57-03085017
Synonyms:
Sevelamer
 
Sevelamero
Sevelamerum
Sévélamer
3
Uric Acidexperimental, investigational14169-93-21175
Synonyms:
1H-Purine-2,6,8-triol
2,6,8-Trihydroxypurine
2,6,8-Trioxopurine
2,6,8-Trioxypurine
 
7,9-dihydro-1H-purine-2,6,8(3H)-trione
Lithate
Lithic acid
Purine-2,6,8(1H,3H,9H)-trione
Urate
Uric acid
4Chelating Agents1423
5Antihypertensive Agents4207
6Angiotensin II Type 1 Receptor Blockers1091
7Angiotensin Receptor Antagonists1191
8Angiotensinogen1177
9
Angiotensin II117868521-88-0, 11128-99-765143, 172198
Synonyms:
1-8-Angiotensin I
1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide
Ang II
Angiotensin 2
Angiotensin II (human)
 
Angiotensin II (mouse)
Angiotonin
Asp-arg-val-TYR-ile-his-pro-phe
Human angiotensin II
Hypertensin
Ile(5)-angiotensin II

Interventional clinical trials:

idNameStatusNCT IDPhase
1Therapeutic Effect of Immunoadsorption for Patients With Lipoprotein GlomerulopathyCompletedNCT00302510
2A Prospective, Single-center, Randomized, Controlled Study of Sevelamer Carbonate in the Lipid Metabolism and Uric Acid Treatment of Obesity-Related GlomerulopathyRecruitingNCT02644486

Search NIH Clinical Center for Lipoprotein Glomerulopathy

Genetic Tests for Lipoprotein Glomerulopathy

About this section

Genetic tests related to Lipoprotein Glomerulopathy:

id Genetic test Affiliating Genes
1 Lipoprotein Glomerulopathy27 24 APOE

Anatomical Context for Lipoprotein Glomerulopathy

About this section

MalaCards organs/tissues related to Lipoprotein Glomerulopathy:

36
Kidney, Endothelial

Publications for Lipoprotein Glomerulopathy

About this section

Articles related to Lipoprotein Glomerulopathy:

(show top 50)    (show all 84)
idTitleAuthorsYear
1
SPONTANEOUS LIPOPROTEIN GLOMERULOPATHY-LIKE NEPHROPATHY IN A SQUIRREL (SCIURUS VULGARIS). (27468047)
2016
2
Macrophage Infiltration into the Glomeruli in Lipoprotein Glomerulopathy. (26955632)
2015
3
Long-term outcome of kidney transplantation in a patient with coexisting lipoprotein glomerulopathy and fibrillary glomerulonephritis. (25852917)
2014
4
Apolipoprotein e mutation and double filtration plasmapheresis therapy on a new chinese patient with lipoprotein glomerulopathy. (25300642)
2014
5
Macrophage-derived apoESendai suppresses atherosclerosis while causing lipoprotein glomerulopathy in hyperlipidemic mice. (25183802)
2014
6
Apolipoprotein E mutations: a comparison between lipoprotein glomerulopathy and type III hyperlipoproteinemia. (24570178)
2014
7
Lipoprotein glomerulopathy: a case report of a rare disease in a Brazilian child. (24676620)
2014
8
Lipoprotein glomerulopathy may provide a key to unlock the puzzles of renal lipidosis. (24487366)
2014
9
A founder haplotype of APOE-Sendai mutation associated with lipoprotein glomerulopathy. (23407349)
2013
10
Thermodynamic and structural destabilization of apoE3 by hereditary mutations associated with the development of lipoprotein glomerulopathy. (23110818)
2013
11
Lipoprotein glomerulopathy in China. (24165683)
2013
12
Lipoprotein glomerulopathy associated with a mutation in apolipoprotein e. (24348079)
2013
13
A possible structural basis behind the pathogenic role of apolipoprotein E hereditary mutations associated with lipoprotein glomerulopathy. (24149834)
2013
14
Hereditary features, treatment, and prognosis of the lipoprotein glomerulopathy in patients with the APOE Kyoto mutation. (24025644)
2013
15
Topics in lipoprotein glomerulopathy: an overview. (24149835)
2013
16
A case of lipoprotein glomerulopathy with thrombotic microangiopathy due to malignant hypertension. (23448537)
2013
17
Identification of a mutation in exon 4 of apolipoprotein E gene in a family affected with lipoprotein glomerulopathy]. (22487820)
2012
18
A rare cause of childhood-onset nephrotic syndrome: lipoprotein glomerulopathy. (22874113)
2012
19
Macrophage impairment produced by Fc receptor gamma deficiency plays a principal role in the development of lipoprotein glomerulopathy in concert with apoE abnormalities. (22863838)
2012
20
Scavenger receptor expressions in the kidneys of mice with lipoprotein glomerulopathy. (22072188)
2012
21
A novel mutation ApoE2 Kurashiki (R158P) in a patient with lipoprotein glomerulopathy. (21467726)
2011
22
Significance of a novel apolipoprotein E variant, ApoE Osaka/Kurashiki, in lipoprotein glomerulopathy. (21670560)
2011
23
Lipoprotein glomerulopathy: first report of 2 not consanguineous Italian men from the same town. (21534236)
2011
24
Lipoprotein glomerulopathy. (21464714)
2011
25
A novel apolipoprotein E mutation, ApoE Osaka (Arg158 Pro), in a dyslipidemic patient with lipoprotein glomerulopathy. (21325775)
2011
26
Successful treatment of lipoprotein glomerulopathy in a daughter and a mother using niceritrol. (20842518)
2010
27
A new apolipoprotein E mutation, apoE Las Vegas, in a European-American with lipoprotein glomerulopathy. (20624773)
2010
28
A rare case of lipoprotein glomerulopathy in a white man: an emerging entity in Asia, rare in the white population. (20121619)
2010
29
Atherosclerosis, inflammation and lipoprotein glomerulopathy in kidneys of apoE-/-/LDL-/- double knockout mice. (20727187)
2010
30
Common apolipoprotein E gene mutations contribute to lipoprotein glomerulopathy in China. (20090368)
2010
31
Improvement of nephrotic syndrome by intensive lipid-lowering therapy in a patient with lipoprotein glomerulopathy. (19603250)
2009
32
Lipoprotein glomerulopathy induced by ApoE-Sendai is different from glomerular lesions in aged apoE-deficient mice. (19459027)
2009
33
A rare cause of nephrotic syndrome: lipoprotein glomerulopathy. (19197098)
2009
34
Lipoprotein glomerulopathy treated with LDL-apheresis (Heparin-induced Extracorporeal Lipoprotein Precipitation system): a case report. (20062740)
2009
35
Clinicopathological and genetic characteristics in Chinese patients with lipoprotein glomerulopathy. (18264944)
2008
36
Renal failure with intracapillary thrombi. Lipoprotein glomerulopathy. (18414445)
2008
37
A novel variant apolipoprotein E Okayama in a patient with lipoprotein glomerulopathy. (18045818)
2008
38
A novel apolipoprotein E mutation, ApoE Tsukuba (Arg 114 Cys), in lipoprotein glomerulopathy. (17967799)
2008
39
Identification of apolipoprotein E Guangzhou (arginine 150 proline), a new variant associated with lipoprotein glomerulopathy. (18046082)
2008
40
APOE Kyoto mutation in European Americans with lipoprotein glomerulopathy. (18077821)
2007
41
Lipoprotein glomerulopathy-like disease in a patient with type III hyperlipoproteinemia due to apolipoprotein E2 (Arg158 Cys)/3 heterozygosity. (17593519)
2007
42
A complete genomic analysis of the apolipoprotein E gene in Chinese patients with lipoprotein glomerulopathy. (17918142)
2007
43
Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. (16431249)
2006
44
Lipoprotein glomerulopathy: a new apolipoprotein E mutation with enhanced glomerular binding. (16490634)
2006
45
Plasma level and genetic variation of apolipoprotein E in patients with lipoprotein glomerulopathy. (15820086)
2005
46
Clinical and pathological analyses of lipoprotein glomerulopathy]. (15181857)
2004
47
Lipoprotein glomerulopathy associated with psoriasis vulgaris: report of 2 cases with apolipoprotein E3/3. (12955707)
2003
48
Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy. (12921981)
2003
49
Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy. (12500244)
2003
50
Chronic graft-versus-host autoimmune disease in Fc receptor gamma chain-deficient mice results in lipoprotein glomerulopathy. (12039982)
2002

Variations for Lipoprotein Glomerulopathy

About this section

UniProtKB/Swiss-Prot genetic disease variations for Lipoprotein Glomerulopathy:

70
id Symbol AA change Variation ID SNP ID
1APOEp.Arg43CysVAR_042734rs121918399
2APOEp.Arg163ProVAR_042735rs121918397

Clinvar genetic disease variations for Lipoprotein Glomerulopathy:

5
id Gene Variation Type Significance SNP ID Assembly Location
1APOENM_ 000041.3(APOE): c.488G> C (p.Arg163Pro)SNVPathogenicrs121918397GRCh37Chr 19, 45412041: 45412041
2APOENM_ 000041.3(APOE): c.127C> T (p.Arg43Cys)SNVPathogenicrs121918399GRCh37Chr 19, 45411100: 45411100

Expression for genes affiliated with Lipoprotein Glomerulopathy

About this section
Search GEO for disease gene expression data for Lipoprotein Glomerulopathy.

Pathways for genes affiliated with Lipoprotein Glomerulopathy

About this section

Pathways related to Lipoprotein Glomerulopathy according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.6APOB, LPA
29.3APOE, LDLR
3
Show member pathways
8.9APOB, APOE, LDLR
4
Show member pathways
8.2APOA2, APOB, APOE, LDLR
5
Show member pathways
8.2APOA2, APOB, APOE, LDLR
6
Show member pathways
7.7APOA2, APOB, APOE, LCAT, LDLR
7
Show member pathways
7.3APOA2, APOB, APOE, LCAT, LDLR, LPA
8
Show member pathways
7.3APOA2, APOB, APOE, LCAT, LDLR, LPA

GO Terms for genes affiliated with Lipoprotein Glomerulopathy

About this section

Cellular components related to Lipoprotein Glomerulopathy according to GeneCards Suite gene sharing:

(show all 13)
idNameGO IDScoreTop Affiliating Genes
1endocytic vesicle lumenGO:007168210.5APOB, APOE
2intermediate-density lipoprotein particleGO:003436310.1APOB, APOE
3chylomicronGO:00426279.9APOA2, APOB, APOE
4endoplasmic reticulum lumenGO:00057889.8APOA2, APOB, APOE
5blood microparticleGO:00725629.7APOA2, APOE, CLU
6spherical high-density lipoprotein particleGO:00343669.7APOA2, CLU
7clathrin-coated endocytic vesicle membraneGO:00306699.7APOB, APOE, LDLR
8high-density lipoprotein particleGO:00343649.4APOA2, APOE, LCAT
9low-density lipoprotein particleGO:00343629.3APOB, APOE, LDLR
10very-low-density lipoprotein particleGO:00343619.1APOA2, APOB, APOE
11early endosomeGO:00057699.0APOA2, APOB, APOE, LDLR
12extracellular regionGO:00055768.3APOA2, APOB, APOE, CLU, LCAT, LPA
13extracellular spaceGO:00056157.7APOA2, APOB, APOE, CLU, LCAT, LDLR

Biological processes related to Lipoprotein Glomerulopathy according to GeneCards Suite gene sharing:

(show all 36)
idNameGO IDScoreTop Affiliating Genes
1artery morphogenesisGO:004884410.5APOB, APOE
2negative regulation of beta-amyloid formationGO:190243010.3APOE, CLU
3protein importGO:001703810.3APOE, CLU
4regulation of beta-amyloid clearanceGO:190022110.3APOE, CLU
5high-density lipoprotein particle assemblyGO:003438010.3APOA2, APOE
6high-density lipoprotein particle clearanceGO:003438410.3APOA2, APOE
7phospholipid effluxGO:003370010.2APOA2, APOE
8positive regulation of cholesterol esterificationGO:001087310.2APOA2, APOE
9triglyceride catabolic processGO:001943310.2APOB, APOE
10phosphatidylcholine biosynthetic processGO:000665610.1APOA2, LCAT
11low-density lipoprotein particle clearanceGO:003438310.0APOB, LDLR
12very-low-density lipoprotein particle clearanceGO:00344479.9APOB, APOE
13cellular protein metabolic processGO:00442679.9APOA2, APOB, APOE
14cholesterol effluxGO:00333449.9APOA2, APOB, APOE
15chylomicron assemblyGO:00343789.8APOA2, APOB, APOE
16chylomicron remodelingGO:00343719.8APOA2, APOB, APOE
17post-translational protein modificationGO:00436879.8APOA2, APOB, APOE
18retinoid metabolic processGO:00015239.8APOA2, APOB, APOE
19triglyceride metabolic processGO:00066419.8APOA2, APOE
20high-density lipoprotein particle remodelingGO:00343759.7APOA2, APOE, LCAT
21chylomicron remnant clearanceGO:00343829.6APOB, APOE, LDLR
22lipoprotein catabolic processGO:00421599.6APOB, APOE, LDLR
23receptor-mediated endocytosisGO:00068989.6APOB, APOE, LDLR
24very-low-density lipoprotein particle remodelingGO:00343729.6APOE, LCAT
25positive regulation of gene expressionGO:00106289.5APOB, CLU, LDLR
26low-density lipoprotein particle remodelingGO:00343749.4APOA2, APOB, APOE, LPA
27lipoprotein biosynthetic processGO:00421589.3APOA2, APOB, APOE, LCAT
28reverse cholesterol transportGO:00436919.2APOA2, APOE, CLU, LCAT
29steroid metabolic processGO:00082029.1APOB, APOE, LCAT, LDLR
30cholesterol transportGO:00303018.9APOA2, APOB, LCAT, LDLR
31lipid transportGO:00068698.6APOA2, APOB, APOE, LDLR, LPA
32cholesterol homeostasisGO:00426328.5APOA2, APOB, APOE, LCAT, LDLR
33cholesterol metabolic processGO:00082038.5APOA2, APOB, APOE, LCAT, LDLR
34transportGO:00068108.3APOA2, APOB, APOE, LDLR, LPA
35lipid metabolic processGO:00066298.1APOB, APOE, CLU, LCAT, LDLR, LPA
36lipoprotein metabolic processGO:00421578.0APOA2, APOB, APOE, LCAT, LDLR, LPA

Molecular functions related to Lipoprotein Glomerulopathy according to GeneCards Suite gene sharing:

(show all 9)
idNameGO IDScoreTop Affiliating Genes
1beta-amyloid bindingGO:000154010.3APOE, CLU
2cholesterol bindingGO:001548510.1APOA2, APOE
3phosphatidylcholine-sterol O-acyltransferase activator activityGO:006022810.0APOA2, APOE
4heparin bindingGO:00082019.9APOB, APOE, LPA
5cholesterol transporter activityGO:00171279.7APOA2, APOB, APOE
6low-density lipoprotein particle receptor bindingGO:00507509.7APOB, APOE, CLU
7lipid bindingGO:00082899.6APOA2, APOB, APOE
8lipid transporter activityGO:00053199.6APOA2, APOB, APOE
9phospholipid bindingGO:00055439.1APOA2, APOB, APOE

Sources for Lipoprotein Glomerulopathy

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet